Huma, a global AI healthcare company based in London, announced Tuesday that it has secured $80 million (around €73.3 million) in a Series D funding round.
Series D was participated in by new and existing strategic and financial investors, including AstraZeneca, HAT SGR’s Hat Technology Fund 4, Hitachi Ventures’ HV Fund, and Bayer’s Leaps.
With this round, the company has already raised over $300 million.
“We are here to accelerate the adoption of digital and AI in healthcare and research, and we do this by making it easier to build digital health solutions for healthcare and research,” says Dan Vahdat, founder and CEO of Huma. “We like to think of the Huma Cloud Platform as Shopify for digital health instead of e-commerce. We believe that when digital and AI scale, they become accessible to the poor and the rich alike. It remains consistent and will help us move from reactive to proactive medicine.”
Homa Cloud Launch
Alongside the D-series, the British company also announced the launch of its Huma Cloud platform.
The platform is a technology ecosystem that aims to support the company’s digital health initiatives and enable others to launch and scale their projects efficiently.
With this cloud platform and its organizational foundation, the company aims to reduce the time required to develop and launch digital health projects at scale, from years to just a few days.
The Huma Cloud platform is designed to support the company’s existing regulated products.
In 2023, the London-based company achieved a milestone by becoming the first and only FDA Class II, EuMDR Class IIb, and Saudi Arabia’s configurable platform for Class C disease diagnostics.
This reduces the cost, time and risk associated with delivering digital health projects through the Huma Cloud platform.
The company is now making this platform available to customers that comes with a software development kit (SDK) to enable rapid development of similar applications or integration of functionality into their existing solutions.
Huma has partnered with Google and other partners to develop advanced AI models, such as “10x Nurse,” that reduce administrative tasks and automate patient assessments with human oversight.
This allows for more efficient management of chronic diseases and real-time monitoring, while supporting startups and small businesses.
This change in focus allows for greater attention to the success of projects or ventures, rather than worrying about scaling technology or managing regulatory burdens.
Homa: Accelerating the adoption of digital solutions
Founded by Dan Vahdat, Homa It is a global AI company in healthcare, with a mission to accelerate the adoption of digital solutions in healthcare and research.
Currently, the company’s standardized platforms are used by more than 3,000 hospitals and clinics, with more than 35 million screened users and 4 million registered healthcare users. They have powered more than 800 studies, supporting nearly 1 million research participants.
The company is known for its role in major national healthcare projects around the world, from the United States and the United Kingdom to Germany, Greece and Saudi Arabia, and in collaboration with most major pharmaceutical companies.
The company says its business in the US has grown significantly since launching the new cashback codes.
Built on the Huma Cloud Platform for respiratory use cases, the RPM product now covers 140,000 contracted lives.
As a result of all these successes, the company has doubled its revenues year after year and aims to achieve profitability this year.
“We have known Huma for several years and have been impressed by their remarkable progress. We have seen this firsthand. They have shown strong growth and excellent metrics. With next-generation AI capabilities and the Huma Cloud platform, Huma can partner with pharmaceutical companies to deliver effective digital health solutions to patients with a focus on predictive and proactive care,” said Dr. Jürgen Eckhardt, Executive Vice President, Head of Development & Licensing, Pharmaceuticals & Pharmaceuticals, Bayer Leaps.
“Writer. Analyst. Avid travel maven. Devoted twitter guru. Unapologetic pop culture expert. General zombie enthusiast.”
